

Virtual Engagement Rehabilitation Assistant (VERA) in the community

Submission date	Recruitment status	<input checked="" type="checkbox"/> Prospectively registered
23/01/2025	Recruiting	<input checked="" type="checkbox"/> Protocol
Registration date	Overall study status	<input type="checkbox"/> Statistical analysis plan
05/03/2025	Ongoing	<input type="checkbox"/> Results
Last Edited	Condition category	<input type="checkbox"/> Individual participant data
22/01/2026	Nervous System Diseases	<input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

The Virtual Engagement Rehabilitation Assistant (VERA) is a new digital tool designed to help patients with their rehabilitation goals. VERA provides access to personalized resources like exercise videos, appointment reminders, well-being questionnaires, and more. This study aims to evaluate how well VERA works in community rehabilitation settings for people with neurological conditions.

Who can participate?

Up to 20 patients receiving neurological community rehabilitation will be invited to participate. Additionally, up to 20 staff members from the rehabilitation teams will also be invited to take part.

What does the study involve?

Participants will use VERA on an iPad for up to six weeks as part of their rehabilitation. They will receive training on how to use VERA and will have access to personalized resources provided by their rehabilitation team. Data collected will include demographic information, health and well-being measures, and feedback on the VERA training. At the end of the six weeks, participants will take part in a semi-structured interview.

What are the possible benefits and risks of participating?

Participants may benefit from having easy access to personalized rehabilitation resources, which could support their recovery. There are minimal risks involved, mainly related to the time commitment required for training and using VERA.

Where is the study run from?

The study is being conducted by the University of Central Lancashire in collaboration with the Lancashire and South Cumbria Foundation Trust and Liverpool University Hospitals Foundation Trust.

When is the study starting and how long is it expected to run for?

February 2024 to April 2026

Who is funding the study?
NIHR Health Technology Assessment programme (UK)

Who is the main contact?
Dr Kathryn Jarvis, KJarvis1@uclan.ac.uk

Contact information

Type(s)
Public, Scientific, Principal investigator

Contact name
Dr Kathryn Jarvis

ORCID ID
<https://orcid.org/0000-0001-5963-7346>

Contact details
University of Central Lancashire, Brook Building Room 247
Preston
United Kingdom
PR1 2HE
+44 1772 892782
KJarvis1@uclan.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)
Nil known

Integrated Research Application System (IRAS)
330807

ClinicalTrials.gov (NCT)
Nil known

Protocol serial number
CPMS 65108, NIHR153944

Study information

Scientific Title
Acceptability and usability of the Virtual Engagement Rehabilitation Assistant (VERA) for community-based neurological rehabilitation

Acronym
VERA in the community

Study objectives

The objectives are:

1. To identify and engage with Virtual Engagement Rehabilitation Assistant (VERA) stakeholders in a community-based setting.
2. To complete the Health Equalities Assessment Tool in collaboration with community stakeholders and undertake identified actions to promote equality of access to and use of VERA during the intervention.
3. To review, prioritise and undertake changes identified in the first VERA (inpatient setting) study to refine the VERA Intervention in preparation for the current study.
4. To utilise findings from Work streams 1 and 2 to modify the VERA Intervention for a community-based neurorehabilitation setting.
5. To implement the VERA Intervention in two community-based neurological rehabilitation services.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 03/12/2024, North West - Preston Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; -; preston.rec@hra.nhs.uk), ref: 24/NW/0321

Study design

Interventional non-randomised qualitative

Primary study design

Interventional

Study type(s)

Quality of life, Treatment

Health condition(s) or problem(s) studied

Neurological rehabilitation

Interventions

Following consent, and collection of demographic information, service users will be invited to take part in the following:

1. Training to learn how to use VERA.
2. Completion of a questionnaire (approximately 10 minutes top complete) to help explore their response to this training
3. Completion of six quantitative measures before using VERA (approximately 35 minutes to complete all six questionnaires): Short-form 36 (SF-36), Patient Health Questionnaire-9 (PHQ-9), Perceived Health Competence Scale (PHCS), Six Item Cognitive Impairment Test (6-CIT), Occupational Self-assessment-Short-form (OSA-SF), Modified Rankin Score (MRS)
4. Use of a VERA Unit for up to six weeks to use within their rehabilitation.
5. On completion of the use of VERA, an interview of up to 60 minutes, which will be conducted online, or face-to-face if this is preferred.
6. Completion of the six quantitative measures after using VERA: SF-36, PHQ-9, PHCS, 6-CIT, OSA-SF, MRS.
7. Debrief

In addition, clinical staff will provide the number of goals set and completed by each participating service user during their time with a VERA Unit. Usage data will also be collected.

Staff working with the service users who have been allocated a VERA Unit will be invited to participate in the study. Up to 10 staff participants from each community neurological rehabilitation service will, following consent and collection of demographic information, will be invited to undertake the following:

1. Training to learn how to use VERA.
2. Completion of a questionnaire to help explore their response to this training
3. Contribute to a focus group of up to 90 minutes (one for each community neurological rehabilitation service). The Focus Group Discussion will be conducted face-to-face if infection control measures and research partner protocols enable face-to-face focus groups. Otherwise they will be conducted online. These groups will take place at a time and venue convenient to the staff.

Intervention Type

Other

Primary outcome(s)

A framework analysis (Ritchie and Spencer 1994) will be used to analyse the data collected

1. Qualitative component: Exploration of the acceptability, feasibility and usability, and information about who may gain benefit/disbenefit from VERA measured using training questionnaires, service-user interviews and the staff focus groups during the intervention
 - 1.1. Experience of receiving training to use VERA
 - 1.2. Experiences of using VERA
 - 1.3. Facilitators and barriers to using VERA
2. Qualitative component: Overall total number of minutes of VERA usage recorded at 6 weeks; Timepoint(s): Post-intervention (6 weeks)

Key secondary outcome(s)

There are no secondary outcome measures

Completion date

30/04/2026

Eligibility

Key inclusion criteria

Service user participants will be eligible for inclusion if they:

1. are receiving, or are on a waiting list to receive, rehabilitation to address the impact of a neurological condition.
2. have rehabilitation goals that a therapist identifies can be addressed through the VERA intervention.
3. have communication that supports effective use of the VERA Unit, either independently or with additional equipment/support. Where an individual has a communication impairment, this will be assessed by a speech and language therapist.
4. are able to understand written English language, or have daily access to someone to offer translation support, as VERA is currently only available in the English language.

Staff participants will be included if they:

1. are a member of the allied health professional staff, either a qualified professional or staff

working in a support role.

2. have worked in their professional capacity with service users who have been allocated a VERA Unit during the implementation phase.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 years

Upper age limit

99 years

Sex

All

Total final enrolment

0

Key exclusion criteria

Service users will be excluded if they:

1. do not have mental capacity to engage in the study. This will be assessed through discussion between the service user, the clinical team and the researchers and, where permission is given, with participant-identified family and friends. This discussion will be based on the five principles of the Mental Capacity Act 2005 Code of Practice (Department for Constitutional Affairs 2007). Individuals will be provided with every support possible to consider their involvement in the study (and their subsequent use of VERA) and to make a decision based on the information provided.
2. are under 18 years of age.

Staff participants will be excluded if they:

1. spend less than seven hours a week working with service users within the community neurological rehabilitation service.
2. are under 18 years of age.

Date of first enrolment

21/07/2025

Date of final enrolment

31/03/2026

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Lancashire & South Cumbria NHS Foundation Trust

Sceptre Point

Sceptre Way

Bamber Bridge

Preston

England

PR5 6AW

Study participating centre

Liverpool University Hospitals NHS Foundation Trust

Royal Liverpool University Hospital

Prescot Street

Liverpool

England

L7 8XP

Sponsor information

Organisation

University of Central Lancashire

ROR

<https://ror.org/010jbqd54>

Funder(s)

Funder type

Government

Funder Name

NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC)

Results and Publications

Individual participant data (IPD) sharing plan

The anonymised, analysis of the interviews and focus groups during the current study will be available upon request from Kathryn Jarvis: KJarvis1@uclan.ac.uk. This analysis will be available once the Executive Summary has been published. We do not have consent from participants to share data for other research.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Service user version 3	14/12/2024	04/03/2025	No	Yes
Participant information sheet	Staff version 3	14/12/2024	04/03/2025	No	Yes
Participant information sheet	Participant information sheet version 3	11/11/2025	11/11/2025	No	Yes
Protocol file		14/12/2024	04/03/2025	No	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes